In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 410-417

  Bonnefoy, Alain ^a   Dupuis Hamelin, Claudine ^a   Steier, Valérie ^a   Delachaume, Carole ^a   Seys, Catherine ^a   Stachyra, Thérèse ^a   Fairley, Monique ^a   Guitton, Michèle ^a   Lampilas, Maxime ^a  

^a SANOFI   (France)

Author keywords

AmpC; Ceftazidime; Combinations; ESBLs

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AVE 1330A; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BICYCLO[3.2.1]OCTANE DERIVATIVE; CEFTAZIDIME; CLAVULANIC ACID; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CITROBACTER; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG STABILITY; ENTEROBACTER; ENTEROBACTERIACEAE; ENZYME INHIBITION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HYDROLYSIS KINETICS; IC 50; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEACEAE; PROTEUS MIRABILIS; SALMONELLA; SERRATIA;

AZEPINES; BACTERIA; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; CLAVULANIC ACID; DEALKYLATION; ENZYME INHIBITORS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; STAPHYLOCOCCUS AUREUS; SULFURIC ACID ESTERS;

EID: 4444347175     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh358     Document Type: Article

References (25)

1. Paterson, D. L. (2000). Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clinical Microbiology and Infection 6, 460-3.
2. Vinokur, P. L., Canton, R., Cesellas, J.-M. et al. (2001). Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western pacific region. Clinical Infectious Diseases 32, Suppl. 2, S94-103.
3. Pfaller, M. A. & Jones, R. N. (2002). Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme, Europe 1997-2000. International Journal of Antimicrobial Agents 19, 383-8.
4. Jones, R. N. (1998). Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the AmpC enzymes. Diagnostic Microbiology and Infectious Disease 31, 461-6.
5. Ballow, C. H. & Schentag, J. J. (1992). Trends in antimicrobial utilization and bacterial resistance: report of the National Resistance Surveillance Group. Diagnostic Microbiology and Infectious Disease 15, Suppl, 37S-42S.
6. Bradford, P. A. (2001). Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews 14, 933-51-57.
7. Philippon, A., Arlet, G. & Jacoby, G. A. (2002). Plasmid-determined AmpC-type β-lactamases. Antimicrobial Agents and Chemotherapy 46, 1-11.
8. Miller, L. A., Ratnam, K. & Payne, D. J. (2001). β-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Current Opinion in Pharmacology 1, 451-8.
9. Aszodi, J., Lampilas, M., Fromentin, C. et al. (2003). Preparation of azabicycles as inhibitors of β-lactamases and their use in pharmaceutical compositions containing β-lactams. Aventis Pharma SA, FIR 2835186, WO 20033063864.
10. Cartwright, S. J. & Waley, S. G. (1984). Purification of β-lactamases by affinity chromatography on phenylboronic acidagarose. Journal of Biochemistry 221, 505-12.
11. Delaire, M., Labia, R. & Samama, J.-P. (1992). Site-directed mutagenesis at the active site of Escherichia coli TEM-1 β -lactamase. Journal of Biological Chemistry 29, 20600-6.
12. BAD promoter. Journal of Bacteriology 14, 4121-30.
13. Lee, N., Yuen, K.-Y. & Kumana, C. R. (2003). Clinical roles of β-lactam/β-lactamase inhibitor combinations. Drugs 63, 1511-24.
14. Payne, D. J., Wensheng, D. & Bateson, J. H. (2000) . β-lactamase epidemiology and the utility of established and novel β-lactamase inhibitors. Expert Opinion on Investigational Drugs 9, 247-61.
15. Jamieson, C. E., Lambert, P. A. & Simpson, I. N. (2003). In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrobial Agents and Chemotherapy 47, 1652-7.
16. Beesley, T., Gascoyne, N., Knott- Hunzicker, V. et al. (1983). The inhibition of C β-lactamases by boronic acids. Biochemical Journal 209, 229-33.
17. Bush, K., Macalintal, C., Rasmussen, B. A. et al. (1993). Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrobial Agents and Chemotherapy 37, 851-8.
18. Livermore, D. M. (1993). Determinants of the activity of β-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy 31, Suppl. A, 9-21.
19. Paterson, D. L., Ko, W.-C., Von Gottberg, A. et al. (2001). Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. Journal of Clinical Microbiology 39, 2206-12.
20. Johnson, D. M., Biedenbach, D. J. & Jones, R. N. (2002). Potency and antimicrobial spectrum update for piperacillin - tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Diagnostic Microbiology and Infectious Disease 43, 49-60.
21. Simpson, I. N., Urch, C. J., Pfaendler, H. R., et al. (2002). Broad-spectrum β-lactamase inhibitor AM-112: synthesis and enhancement of the in vitro activity of ceftazidime and piperacillin, In Program and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002. Abstract F-345, p. 177. American Society for Microbiology, Washington, DC, USA.
22. Moland, E. S., Black, J. A., Ourada, J. et al. (2002). Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 US hospitals. Antimicrobial Agents and Chemotherapy 46, 3837-42.
23. Arpin, C., Dubois, V., Coulange, L. et al. (2003). Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrobial Agents and Chemotherapy 47, 3506-14.
24. Kitziz, M. D., Ferré, B., Coutrot, A. et al. (1989). In vitro activity of combinations of β-lactam antibiotics with β -lactamase inhibitors against cephalosporinase-producing bacteria. European Journal of Clinical Microbiology and Infectious Diseases 8, 783-8.
25. Nakagawa, K., Momono, S., Sasaki, Y. U. et al. (1990). Preoperative administration of a sulbactam/cefoperazone mixture during cholecystectomy. Surgical Care 32, 875-9.